Genomics Global Market – Forecast To 2027

Publishing Date : November, 2020
Report Code : HCBT 0110
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Genomics is the branch of biotechnology where different techniques of genetics and molecular biology are employed to map the DNA sequences of targeted genes or the complete set of genomes of interest and then organizing the results in the database and application of data in various fields. Genomics technologies are gaining popularity as they play important role in the early disease diagnosis, prognosis, disease progression monitoring, recurrence monitoring; personalized medicine along with playing a vital role in the discovery & development (target identification and validation of new targets for drugs), plant genome studies, forensics, and food technology, etc.

According to IQ4I analysis, the genomics global market is expected to reach $31,835.9 million by 2027 growing at a mid single digit CAGR from 2020 to 2027. The factors driving the genomics market are demand for early disease detection, diagnosis, and treatment, rising government and private funding, reduced cost of genomics test and favorable reimbursement, increasing demand for personalized medicine, increasing application of genomics in drug discovery & development and technological advancements. Whereas, factors restraining the market growth are high cost of instruments and special research materials, analytical validity of the result, lack of standardization, complexity, lack of skilled professionals, and factors such as stringent and time-consuming regulatory guidelines, data security and regulatory issues, large data management issues are threats to market growth.

The genomics market is classified into products, applications, end-user, and geography. The products market is further segmented into instruments, consumables, software & services, and genomics services, among them, consumables segment accounted for the largest revenue in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The genomic services is fastest growing segment and is expected to grow at a high single digit CAGR from 2020 to 2027.

The instruments market is further sub-segmented into Polymerase Chain Reaction (PCR) instrument, sequencing instruments, Nucleic acid extraction, and purification instruments, In-situ hybridization (ISH) instruments, DNA Microarray instruments, Isothermal Nucleic Acid Amplification Technology (INAAT) instruments and other instruments. Among them, the Polymerase Chain reaction (PCR) instruments segment accounted for the largest revenue of in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027. This is attributed to extensive use of PCR (qPCR) use in diagnostics-i.e., lab-based tests- early screening, prognosis, recurrence screening, NIPT, organ transplantation, food and agriculture and also advancement in PCR systems, launch of advanced PCR instruments, automated workflows, increasing approvals of PCR bases assays for medical diagnosis and other applications. But, disadvantages like as high specificity of experimental condition, specificity alteration of the targeted DNA, errors due to the inherent nature of DNA polymerase, the requirement of prior sequence information to design primers, lack of technical professionals and also value added advantages of NGS will restrain the use of PCR market. The sequencing is fastest growing instruments segment at a low single digit CAGR from 2020 to 2027. The software and services market is estimated to be $xx million in 2020 and is expected to grow at a low single digit CAGR from 2020 to 2027.

The consumables market is further segmented into Polymerase Chain reaction (PCR) consumables, sequencing consumables, nucleic acid extraction and purification consumables, In-Situ Hybridization (ISH) consumables, DNA Microarray consumables, Isothermal Nucleic Acid Amplification Technology (INAAT) consumables, and other consumables. Among them, the Polymerase Chain reaction (PCR) consumables segment accounted for the largest revenue in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. This is attributed to the increased demand for molecular (PCR) based test for disease detection especially in infectious disease, early disease screening, prenatal testing, increased application of PCR in crop variety identification & development, forensics, species identification (virus, bacteria), and evolutionary studies. The sequencing is fastest growing consumables segment at a high single digit CAGR from 2020 to 2027. This is attributed to the low cost of NGS based tests, increasing awareness about NGS based genetic testing, advancements in NGS based technologies, increased focus in developing NGS based panel test for early screening and also increasing focus in the  application NGS in in drug discovery and development programs, crop improvement, forensics science, and food technology.

The Genomics Service market is segmented into NGS Services, PCR Services, Microarray Services, and other services. Among these, NGS Services is largest and fastest growing segment in 2020 and are expected to grow at high single digit CAGR from 2020 to 2027 due to increasing adoption of NGS based tests over other tools, reduced cost of NGS based tests, and favorable reimbursement facility for gene testing.

Based on application, the market is segmented into diagnostics, drug discovery & development, plant genomics, and other applications. Among these, the diagnostics is largest &fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027. This is attributed to the outbreak of various infectious diseases like influenza, Ebola, COVID-19 in recent years, adoption of early screening, companion diagnostic tests, prenatal screening of genetic diseases, favorable reimbursement facility, and advancements in analytical tools, etc. The diagnostics market is further sub-segmented into infectious and non-infectious, among which, the infectious segment generated the largest revenue of in 2020 and is expected to grow at mid single digit CAGR from 2020 to 2027. The non-infectious segment is fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027. This is attributed to the all-embracing use of PCR and NGS based tests in diagnostics mainly for early screening of oncology diseases, and other CNS and metabolic diseases.

The end-users of genomics market is segmented into Pharma & Biotech, Hospital & Clinical Laboratories, Contract Research Organization (CRO's) and others. Among the end-users, Hospital & Clinical Laboratories segment accounted for the largest revenue in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. This is mainly attributed to the increase in early screening, genetic testing, and diagnostics tests and kits developed for the same that are mainly conducted in hospital laboratories, prescribing for companion diagnostics, etc. The Contract Research Organization (CRO's) is fastest growing segment at high single digit CAGR from 2020 to 2027 due to increased outsourcing for maximum utilization of genomic technologies in drug discovery process, the launch of new genomic services and increasing capabilities to offer end-to-end genomic services.

By Geography, the genomics global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy, and Rest of Europe), Asia-Pacific (Japan, China, India and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and the Middle East & Africa). Among these, the North America region dominated the genomics global market with a share of xx% accounting for the largest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. This is attributed to increased incidence of cancer & other metabolic diseases, increased awareness about the early screening & disease detection, prenatal and genetic testing, gene editing, presence of major players and popular research institutes increase funding, favorable reimbursement facilities, research in crop improvement, presence of advanced technologies & skilled labors are expected to drive the genomics market in North American region. Asia-Pacific is fastest growing region in Genomics market and is expected to grow double digit CAGR from 2020 to 2027.

The Genomics market is consolidated with the 6 top players occupying xx% of the market share and the remaining xx% of the market is occupied by other players and service providers. The key players in Genomics Global Market include F. Hoffmann-La Roche Ltd. (Switzerland), Illumina Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Qiagen N.V. (Netherlands), Danaher Corporation. (U.S.), Exact Sciences Corporation (U.S.), Myriad Genetics (U.S.) Bio-Rad Laboratories, Inc. (U.S.), Hologic, Inc (U.S.), Merck KGaA (Germany), Abbott Laboratories (U.S.), BGI Genomics (China) and others.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • The Middle East and Africa
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     DEMAND FOR EARLY DISEASE DETECTION, DIAGNOSIS, AND TREATMENT
        • 3.3.1.2     RISING GOVERNMENT AND PRIVATE FUNDING
        • 3.3.1.3     REDUCED COST OF GENOMIC TEST AND FAVORABLE REIMBURSEMENT
        • 3.3.1.4     INCREASING DEMAND FOR PERSONALIZED MEDICINE
        • 3.3.1.5     RISING APPLICATION OF GENOMICS IN DRUG DISCOVERY AND DEVELOPMENT
        • 3.3.1.6     TECHNOLOGICAL ADVANCEMENTS FAVORING GENOMICS ADOPTION
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     HIGH COST OF INSTRUMENTS AND SPECIAL RESEARCH MATERIALS
        • 3.3.2.2     ANALYTICAL VALIDITY OF RESULT, LACK OF STANDARDIZATION, COMPLEXITY
        • 3.3.2.3     LACK OF SKILLED PROFESSIONALS
        • 3.3.2.4     STRINGENT AND TIME-CONSUMING REGULATORY GUIDELINES
        • 3.3.2.5     DATA SECURITY AND LARGE DATA MANAGEMENT ISSUES
    • 3.4     SELECTED GENOMICS PRODUCTS, CONSUMABLES AND SERVICES PRICE LIST
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.
      • 3.5.2     EUROPE
      • 3.5.3     CHINA
      • 3.5.4     JAPAN
      • 3.5.5     SOUTH KOREA
      • 3.5.6     BRAZIL
    • 3.6     REIMBURSEMENT SCENARIO
    • 3.7     PATENT ANALYSIS
    • 3.8     FUNDING SCENARIO
    • 3.9     CLINICAL TRIALS
    • 3.10     GENOMICS – DEALS, APPROVALS AND NEW PRODUCT LAUNCH
      • 3.10.1     GENOMICS-DEALS
      • 3.10.2     NEW PRODUCT AND SERVICE LAUNCH
    • 3.11     TECHNOLOGICAL ADVANCEMENTS
      • 3.11.1     INTRODUCTION
      • 3.11.2     EXPANSION OF SINGLE CELL BIOLOGY
      • 3.11.3     ADVANCEMENTS IN DATA ANALYSIS DATABASES
      • 3.11.4     ADVANCEMENTS IN MACHINE LEARNING AND ARTIFICIAL INTELLIGENCE
      • 3.11.5     ADVANCEMENT IN GENOME EDITING
      • 3.11.6     CRISPER SCREENING AND DIAGNOSTICS
      • 3.11.7     LONG READING SEQUENCING TECHNOLOGY (THIRD GENERATION SEQUENCING)
    • 3.12     PORTER’S FIVE FORCE ANALYSIS
      • 3.12.1     THREAT OF NEW ENTRANTS
      • 3.12.2     THREAT OF SUBSTITUTES
      • 3.12.3     RIVALRY AMONG EXISTING COMPETITORS
      • 3.12.4     BARGAINING POWER OF SUPPLIERS
      • 3.12.5     BARGAINING POWER OF BUYERS
    • 3.13     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.13.1     GENOMICS GLOBAL MARKET SHARE ANALYSIS
  • 4     GENOMICS GLOBAL MARKET, BY PRODUCTS
    • 4.1     INTRODUCTION
    • 4.2     INSTRUMENTS
      • 4.2.1     POLYMERASE CHAIN REACTION
      • 4.2.2     SEQUENCING
      • 4.2.3     NUCLEIC ACID EXTRACTION AND PURIFICATION
      • 4.2.4     IN-SITU HYBRIDIZATION
      • 4.2.5     DNA MICROARRAY
      • 4.2.6     ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
      • 4.2.7     OTHER INSTRUMENTS
    • 4.3     CONSUMABLES
      • 4.3.1     POLYMERASE CHAIN REACTION (PCR)CONSUMABLES
      • 4.3.2     SEQUENCING CONSUMABLES
      • 4.3.3     NUCLEIC ACID EXTRACTION & PURIFICATION CONSUMABLES
      • 4.3.4     DNA MICROARRAY CONSUMABLES
      • 4.3.5     IN-SITU HYBRIDIZATION CONSUMABLES
      • 4.3.6     ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY CONSUMABLES
      • 4.3.7     OTHER CONSUMABLES
    • 4.4     SOFTWARE AND SERVICES
    • 4.5     GENOMIC SERVICES
      • 4.5.1     NGS SERVICES
      • 4.5.2     PCR SERVICES
      • 4.5.3     MICROARRAY SERVICES
      • 4.5.4     OTHER GENOMICS SERVICES
  • 5     GENOMICS GLOBAL MARKET, BY APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     DIAGNOSTICS
      • 5.2.1     INFECTIOUS DISEASE
      • 5.2.2     NON-INFECTIOUS DISEASE
    • 5.3     DRUG DISCOVERY AND DEVELOPMENT
    • 5.4     PLANT GENOMICS
    • 5.5     OTHERS
  • 6     GENOMICS GLOBAL MARKET, BY END-USERS
    • 6.1     INTRODUCTION
    • 6.2     PHARMA AND BIOTECH
    • 6.3     HOSPITALS AND CLINICAL LABORATORIES
    • 6.4     CONTRACT RESEARCH ORGANIZATION
    • 6.5     OTHERS
  • 7     GENOMICS GLOBAL MARKET, BY REGION
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF N.A.
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     ITALY
      • 7.3.4     REST OF EUROPE
    • 7.4     ASIA-PACIFIC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     INDIA
      • 7.4.4     REST OF APAC
    • 7.5     REST OF THE WORLD
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATIN AMERICA
      • 7.5.3     MIDDLE EAST AND AFRICA
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     NEW PRODUCT LAUNCH
    • 8.3     AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 8.4     APPROVAL
    • 8.5     ACQUISITION
    • 8.6     EXPANSION
    • 8.7     OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     ABBOTT LABORATORIES
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     BGI GENOMICS
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BIO-RAD LABORATORIES, INC
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     DANAHER CORPORATION
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     EXACT SCIENCES CORPORATION
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     HOLOGIC, INC.
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     ILLUMINA, INC.
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     MERCK KGAA
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     MYRIAD GENETICS, INC.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     QIAGEN N.V
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS
    • 9.11     F. HOFFMANN-LA ROCHE LTD
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     PRODUCT PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     BUSINESS STRATEGY
      • 9.11.6     SWOT ANALYSIS
    • 9.12     THERMO FISHER SCIENTIFIC, INC.
      • 9.12.1     OVERVIEW
      • 9.12.2     FINANCIALS
      • 9.12.3     PRODUCT PORTFOLIO
      • 9.12.4     KEY DEVELOPMENTS
      • 9.12.5     BUSINESS STRATEGY
      • 9.12.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     GENOMICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 2     GENOMICS GLOBAL MARKET REVENUE, BY PRODUCT (2019-2027) ($MN)
      • TABLE 3     INSTRUMENTS GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2019-2027) ($MN)
      • TABLE 4     INSTRUMENT GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 5     PCR GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 6     SEQUENCING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 7     NUCLEIC ACID EXTRACTION & PURIFICATION GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 8     IN-SITU HYBRIDIZATION GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 9     DNA MICROARRAY GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 10     ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 11     OTHER INSTRUMENT GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 12     CONSUMABLES GLOBAL MARKET REVENUE, BY PRODUCT (2019-2027) ($MN)
      • TABLE 13     CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 14     PCR CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 15     SEQUENCING CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 16     NUCLEIC ACID EXTRACTION & PURIFICATION CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 17     DNA MICROARRAY CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 18     IN-SITU HYBRIDIZATION CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 19     INAAT CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 20     OTHER CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 21     SOFTWARE AND SERVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 22     GENOMICS SERVICES GLOBAL MARKET REVENUE, BY TECHNOLOGY (2019-2027) ($MN)
      • TABLE 23     GENOMICS SERVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 24     NGS SERVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 25     NGS SERVICES MATRIX
      • TABLE 26     PCR SERVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 27     PCR SERVICES MATRIX
      • TABLE 28     MICROARRAY SERVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 29     MICROARRAY SERVICES MATRIX
      • TABLE 30     OTHER GENOMICS SERVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 31     GENOMICS GLOBAL MARKET REVENUE, BY APPLICATION (2019-2027) ($MN)
      • TABLE 32     DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027)($MN)
      • TABLE 33     DIAGNOSTICS GLOBAL MARKET REVENUE, BY DISEASE TYPE(2019-2027) ($MN)
      • TABLE 34     INFECTIOUS DISEASE GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 35     NON-INFECTIOUS DISEASE GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 36     DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 37     PLANT GENOMICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 38     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 39     GENOMICS GLOBAL MARKET REVENUE, BY END-USERS (2019-2027) ($MN)
      • TABLE 40     PHARMA AND BIOTECH GLOBAL MARKET REVENUE, BY REGION (2020-2027) ($MN)
      • TABLE 41     HOSPITAL AND CLINICAL LAB GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 42     CONTRACT RESEARCH ORGANIZATION GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 43     OTHER END-USERS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 44     GENOMICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 45     NORTH AMERICA GENOMICS MARKET REVENUE, BY PRODUCT (2019-2027) ($MN)
      • TABLE 46     NORTH AMERICA INSTRUMENT MARKET REVENUE, BY PRODUCT TYPE (2019-2027) ($MN)
      • TABLE 47     NORTH AMERICA CONSUMABLE MARKET REVENUE, BY PRODUCT TYPE (2019-2027) ($MN)
      • TABLE 48     NORTH AMERICA GENOMICS SERVICES MARKET REVENUE, BY TECHNOLOGY TYPE (2019-2027) ($MN)
      • TABLE 49     NORTH AMERICA GENOMICS MARKET REVENUE, BY APPLICATION (2019-2027) ($MN)
      • TABLE 50     NORTH AMERICA DIAGNOSTICS MARKET REVENUE, BY DISEASE (2019-2027) ($MN)
      • TABLE 51     NORTH AMERICA GENOMICS MARKET REVENUE, BY END-USERS (2019-2027) ($MN)
      • TABLE 52     NORTH AMERICA GENOMICS MARKET REVENUE, BY COUNTRY (2019-2027) ($MN)
      • TABLE 53     EUROPE GENOMICS MARKET REVENUE, BY PRODUCT (2019-2027) ($MN)
      • TABLE 54     EUROPE INSTRUMENT MARKET REVENUE, BY PRODUCT TYPE (2019-2027) ($MN)
      • TABLE 55     EUROPE CONSUMABLE MARKET REVENUE, BY PRODUCT TYPE (2019-2027) ($MN)
      • TABLE 56     EUROPE GENOMICS SERVICES MARKET REVENUE, BY TECHNOLOGY TYPE (2019-2027) ($MN)
      • TABLE 57     EUROPE GENOMICS MARKET REVENUE, BY APPLICATION (2019-2027) ($MN)
      • TABLE 58     EUROPE DIAGNOSTICS MARKET REVENUE, BY DISEASE (2019-2027) ($MN)
      • TABLE 59     EUROPE GENOMICS MARKET REVENUE, BY END-USERS (2019-2027) ($MN)
      • TABLE 60     EUROPE GENOMICS MARKET REVENUE, BY COUNTRY (2019-2027) ($MN)
      • TABLE 61     ASIA-PACIFIC GENOMICS MARKET REVENUE, BY PRODUCT (2019-2027) ($MN)
      • TABLE 62     ASIA-PACIFIC INSTRUMENT MARKET REVENUE, BY PRODUCT TYPE (2019-2027) ($MN)
      • TABLE 63     ASIA-PACIFIC CONSUMABLE MARKET REVENUE, BY PRODUCT TYPE (2019-2027) ($MN)
      • TABLE 64     ASIA-PACIFIC GENOMICS SERVICES MARKET REVENUE, BY TECHNOLOGY TYPE (2019-2027) ($MN)
      • TABLE 65     ASIA-PACIFIC GENOMICS MARKET REVENUE, BY APPLICATION (2019-2027) ($MN)
      • TABLE 66     ASIA-PACIFIC DIAGNOSTICS MARKET REVENUE, BY DISEASE (2019-2027) ($MN)
      • TABLE 67     ASIA-PACIFIC GENOMICS MARKET REVENUE, BY END-USERS (2019-2027) ($MN)
      • TABLE 68     ASIA-PACIFIC GENOMICS MARKET REVENUE, BY COUNTRY (2019-2027) ($MN)
      • TABLE 69      REST OF THE WORLD GENOMICS MARKET REVENUE, BY PRODUCT (2019-2027) ($MN)
      • TABLE 70     REST OF THE WORLD INSTRUMENT MARKET REVENUE, BY PRODUCT TYPE (2019-2027) ($MN)
      • TABLE 71     REST OF THE WORLD CONSUMABLE MARKET REVENUE, BY PRODUCT TYPE (2019-2027) ($MN)
      • TABLE 72     REST OF THE WORLD GENOMICS SERVICES MARKET REVENUE, BY TECHNOLOGY TYPE (2019-2027) ($MN)
      • TABLE 73     REST OF THE WORLD GENOMICS MARKET REVENUE, BY APPLICATION (2019-2027) ($MN)
      • TABLE 74     REST OF THE WORLD DIAGNOSTICS MARKET REVENUE, BY DISEASE (2019-2027) ($MN)
      • TABLE 75     REST OF THE WORLD GENOMICS MARKET REVENUE, BY END-USERS (2019-2027) ($MN)
      • TABLE 76     REST OF THE WORLD GENOMICS MARKET REVENUE, BY COUNTRY (2019-2027) ($MN)
      • TABLE 77     NEW PRODUCT LAUNCH (2019-2020)
      • TABLE 78     AGREEMENTS, PARTNERSHIPS & COLLABORATIONS (2019-2020)
      • TABLE 79     APPROVALS ( 2019-2020)
      • TABLE 80     ACQUISITION(2019-2020)
      • TABLE 81     EXPANSION (2019-2020)
      • TABLE 82     OTHERS ( 2019-2020)
      • TABLE 83     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q2) ($MN)
      • TABLE 84     ABBOTT LABORATORIES: TOTAL REVENUE BY SEGMENT, (2018-2020) (Q2)($MN)
      • TABLE 85     ABBOTT LABORATORIES: TOTAL REVENUE, BY REGION, (2018-2020) (Q2) ($MN)
      • TABLE 86     BGI GENOMICS: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q2) ($MN)
      • TABLE 87     BIO-RAD LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q2) ($MN)
      • TABLE 88     BIO-RAD LABORATORIES: TOTAL REVENUE BY SEGMENT, (2018-2020) (Q2)($MN)
      • TABLE 89     BIO-RAD LABORATORIES: TOTAL REVENUE, BY REGION, (2018-2020) (Q2) ($MN)
      • TABLE 90     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2018-2020) (Q2)($MN)
      • TABLE 91     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2018-2020) (Q2) ($MN)
      • TABLE 92     DANAHER CORPORATION: TOTAL REVENUE, BY REGION, (2018-2020) (Q2) ($MN)
      • TABLE 93     EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q2) ($MN)
      • TABLE 94     EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY SEGMENT, (2018-2020) (Q2) ($MN)
      • TABLE 95     EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) (Q2)($MN)
      • TABLE 96     HOLOGIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q3) ($MN)
      • TABLE 97     HOLOGIC, INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) (Q3) ($MN)
      • TABLE 98     HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) (Q3) ($MN)
      • TABLE 99     ILLUMINA, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q2)($MN)
      • TABLE 100     ILLUMINA, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) (Q2) ($MN)
      • TABLE 101     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q2) ($MN)
      • TABLE 102     MERCK KGAA: TOTAL REVENUE, BY SEGMENT, (2018-2020) (Q2) ($MN)
      • TABLE 103     MERCK KGAA COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) (Q2) ($MN)
      • TABLE 104     MYRIAD GENETICS, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 105     MYRIAD GENETICS.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 106     MYRIAD GENETICS: DIAGNOSTICS AND OTHER PRODUCTS TOTAL REVENUE, BY SUB-SEGMENT (2018-2020) ($MN)
      • TABLE 107     QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2018 -2020) (Q2) ($MN)
      • TABLE 108     QIAGEN N.V.: TOTAL REVENUE BY SEGMENT, (2018-2020) (Q2) ($MN)
      • TABLE 109     QIAGEN N.V.: TOTAL REVENUE, BY REGION, (2018-2020) (Q2) ($MN)
      • TABLE 110     F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE AND R&D EXPENSES (2018-2020) (Q2) ($MN)
      • TABLE 111      F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE, BY SEGMENT, (2018-2020) (Q2) ($MN)
      • TABLE 112     F. HOFFMANN-LA ROCHE LTD: DIAGNOSTICS REVENUE, BY SUB-SEGMENT, (2018-2020) (Q2) ($MN)
      • TABLE 113     F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE, BY REGION, (2018-2020) (Q2) ($MN)
      • TABLE 114     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q2) ($MN)
      • TABLE 115     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) (Q2) ($MN)
      • TABLE 116     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) (Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     GENOMICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: GENOMICS GLOBAL MARKET
      • FIGURE 3     GENOMICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     GENOMICS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     GENOMICS GLOBAL MARKET SHARE: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     GENOMICS GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     GENOMICS WORKFLOW
      • FIGURE 9     GENOMICS MARKET: PATENT FILING, BY MAJOR PLAYERS (2016-2020)
      • FIGURE 10     GENOMICS FUNDING SCENARIO, BY APPLICATION (2019-2020)
      • FIGURE 11     GENOMICS FUNDING SCENARIO, BY INDICATION, (2019-2020)
      • FIGURE 12     GENOMICS CLINICAL TRIALS, BY INDICATION, (2019-2020)
      • FIGURE 13     GENOMICS GLOBAL MARKET: PORTER’S FIVE FORCE ANALYSIS
      • FIGURE 14     GENOMICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 15     GENOMICS GLOBAL MARKET SHARE, BY PRODUCT (2020 VS 2027) (%)
      • FIGURE 16     INSTRUMENT GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020) CAGR (%)
      • FIGURE 17     CONSUMABLES GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020 VS 2027) (%)
      • FIGURE 18     PCR CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 19     SEQUENCING CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 20     NUCLEIC ACID EXTRACTION & PURIFICATION CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 21     DNA MICROARRAY CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 22     IN-SITU HYBRIDIZATION CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 23     OTHER CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 24     GENOMICS SERVICES GLOBAL MARKET SHARE, BY TECHNOLOGY (2020 VS 2027) (%)
      • FIGURE 25     GENOMICS GLOBAL MARKET SHARE, BY APPLICATION (2020 VS 2027) (%)
      • FIGURE 26     DIAGNOSTICS GLOBAL MARKET REVENUE, BY DISEASE TYPE (2020 VS 2027) ($MN)
      • FIGURE 27     INFECTIOUS DISEASE MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 28     DRUG DISCOVERY AND DEVELOPMENT GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 29     PLANT GENOMICS GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 30     OTHER APPLICATIONS GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 31     GENOMICS GLOBAL MARKET SHARE, BY END-USERS (2020 VS 2027) (%)
      • FIGURE 32     HOSPITAL AND CLINICAL LABS MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 33     CONTRACT RESEARCH ORGANIZATION GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 34     GENOMICS GLOBAL MARKET REVENUE, BY GEOGRAPHY (2019-2027) ($MN)
      • FIGURE 35     GENOMICS GLOBAL MARKET SHARE BY REGION AND REVENUE BY COUNTRY (2020) (%)($MN)
      • FIGURE 36     NORTH AMERICA GENOMICS MARKET SHARE, BY PRODUCT (2020 VS 2027) (%)
      • FIGURE 37     NORTH AMERICA INSTRUMENT MARKET SHARE, BY PRODUCT TYPE (2020) CAGR (%)
      • FIGURE 38     NORTH AMERICA CONSUMABLE MARKET SHARE, BY PRODUCT TYPE (2020 VS 2027) (%)
      • FIGURE 39     NORTH AMERICA GENOMICS SERVICE MARKET SHARE, BY TECHNOLOGY TYPE (2020 VS 2027) (%)
      • FIGURE 40     NORTH AMERICA GENOMICS MARKET SHARE, BY APPLICATION (2020 VS 2027) (%)
      • FIGURE 41     NORTH AMERICA DIAGNOSTICS MARKET SHARE, BY DISEASE (2020 VS 2027) (%)
      • FIGURE 42     NORTH AMERICA GENOMICS MARKET SHARE, BY END-USER (2020 VS 2027) (%)
      • FIGURE 43     NORTH AMERICA GENOMICS GLOBAL MARKET REVENUE, BY COUNTRY (2020 VS 2027) ($MN)
      • FIGURE 44     U.S. GENOMICS GLOBAL MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 45     U.S. GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 46     REST OF NORTH AMERICA GENOMICS GLOBAL MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 47     REST OF NORTH AMERICA GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 48     EUROPE GENOMICS MARKET SHARE, BY PRODUCT (2020 VS 2027) (%)
      • FIGURE 49     EUROPE INSTRUMENT MARKET SHARE, BY PRODUCT TYPE (2020) CAGR (%)
      • FIGURE 50     EUROPE CONSUMABLE MARKET SHARE, BY PRODUCT TYPE (2020 VS 2027) (%)
      • FIGURE 51     EUROPE GENOMICS SERVICE MARKET SHARE, BY TECHNOLOGY TYPE (2020 VS 2027) (%)
      • FIGURE 52     EUROPE GENOMICS MARKET SHARE, BY APPLICATION (2020 VS 2027) (%)
      • FIGURE 53     EUROPE DIAGNOSTICS MARKET SHARE, BY DISEASE (2020 VS 2027) (%)
      • FIGURE 54     EUROPE GENOMICS MARKET SHARE, BY END-USER (2020 VS 2027) (%)
      • FIGURE 55     EUROPE GENOMICS MARKET SHARE, BY COUNTRY (2020 VS 2027) (%)
      • FIGURE 56     GERMANY GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 57     GERMANY GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 58     FRANCE GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 59     FRANCE GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 60     ITALY GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 61     ITALY GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 62     REST OF EUROPE GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 63     REST OF EUROPE GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 64     ASIA-PACIFIC GENOMICS MARKET SHARE, BY PRODUCT (2020 VS 2027) (%)
      • FIGURE 65     ASIA-PACIFIC INSTRUMENT MARKET SHARE, BY PRODUCT TYPE (2020) CAGR (%)
      • FIGURE 66     ASIA-PACIFIC CONSUMABLE MARKET SHARE, BY PRODUCT TYPE (2020 VS 2027) (%)
      • FIGURE 67     ASIA-PACIFIC GENOMICS SERVICE MARKET SHARE, BY TECHNOLOGY TYPE (2020 VS 2027) (%)
      • FIGURE 68     ASIA-PACIFIC GENOMICS MARKET SHARE, BY APPLICATION (2020 VS 2027) (%)
      • FIGURE 69     ASIA-PACIFIC DIAGNOSTICS MARKET SHARE, BY DISEASE (2020 VS 2027) (%)
      • FIGURE 70     ASIA-PACIFIC GENOMICS MARKET SHARE, BY END-USER (2020 VS 2027) (%)
      • FIGURE 71     ASIA-PACIFIC GENOMICS MARKET SHARE, BY COUNTRY (2020 VS 2027) (%)
      • FIGURE 72     JAPAN GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 73     JAPAN GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 74     CHINA GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 75     CHINA GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 76     INDIA GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 77     INDIA GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 78      REST OF APAC GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 79     REST OF APAC GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 80     REST OF THE WORLD GENOMICS MARKET SHARE, BY PRODUCT (2020 VS 2027) (%)
      • FIGURE 81     REST OF THE WORLD INSTRUMENT MARKET SHARE, BY PRODUCT TYPE (2020) CAGR (%)
      • FIGURE 82     REST OF THE WORLD CONSUMABLE MARKET SHARE, BY PRODUCT TYPE (2020 VS 2027) (%)
      • FIGURE 83     REST OF THE WORLD GENOMICS SERVICE MARKET SHARE, BY TECHNOLOGY TYPE (2020 VS 2027) (%)
      • FIGURE 84     REST OF THE WORLD GENOMICS MARKET SHARE, BY APPLICATION (2020 VS 2027) (%)
      • FIGURE 85     REST OF THE WORLD DIAGNOSTICS MARKET SHARE, BY DISEASE (2020 VS 2027) (%)
      • FIGURE 86     REST OF THE WORLD GENOMICS MARKET SHARE, BY END-USER (2020 VS 2027) (%)
      • FIGURE 87     REST OF THE WORLD GENOMICS MARKET SHARE, BY COUNTRY (2020 VS 2027) (%)
      • FIGURE 88     BRAZIL GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 89     BRAZIL GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 90     REST OF LATAM GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 91     REST OF LATAM GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 92     MIDDLE EAST AND AFRICA GENOMICS MARKET REVENUE, BY PRODUCT (2020 VS 2027) ($MN)
      • FIGURE 93     MIDDLE EAST AND AFRICA GENOMICS MARKET REVENUE, BY APPLICATION & END-USERS (2020 VS 2027) ($MN)
      • FIGURE 94     KEY GROWTH STRATEGIES (2019-2020)
      • FIGURE 95     SWOT: ABBOTT LABORATORIES
      • FIGURE 96     SWOT: BGI GENOMICS
      • FIGURE 97     SWOT: BIO-RAD LABORATORIES
      • FIGURE 98     SWOT: DANAHER CORPORATION
      • FIGURE 99     SWOT: EXACT SCIENCES CORPORATION
      • FIGURE 100     SWOT: HOLOGIC, INC.
      • FIGURE 101     SWOT: ILLUMINA, INC.
      • FIGURE 102     SWOT: MERCK KGAA
      • FIGURE 103     SWOT: MYRIAD GENETICS, INC.
      • FIGURE 104     SWOT: QIAGEN N.V.
      • FIGURE 105     SWOT: F. HOFFMANN-LA ROCHE LTD
      • FIGURE 106     SWOT: THERMO FISHER SCIENTIFIC, INC.

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     10X GENOMICS (U.S.)
      • 2     23ANDME (U.S.)
      • 3     3DBIOSURFACE TECHNOLOGIES, LLC (U.S)
      • 4     ABBOTT LABORATORIES, INC. (U.S.)
      • 5     ABM INC.(APPLIED BIOLOGICAL MATERIALS INC. ) (U.S.)
      • 6     ACT GENOMICS HOLDINGS CO., LTD (CHINA)
      • 7     ADM LIFESEQUENCING (SPAIN)
      • 8     ADVANCED CELL DIAGNOSTICS, INC. (U.S.)
      • 9     AGENA BIOSCIENCE, INC. (U.S.)
      • 10     AGILENT TECHNOLOGIES, INC. (U.S.)
      • 11     ALLELE LIFE SCIENCES PRIVATE LIMITED (INDIA)
      • 12     ALLERGAN, PLC (IRELAND)
      • 13     ALTONA DIAGNOSTICS GMBH (GERMANY)
      • 14     AMBRY GENETICS CORPORATION (U.S.)
      • 15     AMOY DIAGNOSTICS (CHINA)
      • 16     ANALYTICAL BIOSCIENCES LIMITED (U.S.)
      • 17     ANCESTRY HEALTH (U.S.)
      • 18     ANNOROAD GENE TECHNOLOGY CO., LTD. (CHINA)
      • 19     ANPAC TECHNOLOGY USA (ANPAC BIO) (U.S.)
      • 20     APPLIED MICROARRAYS, INC (U.S.)
      • 21     ARRAYGEN TECHNOLOGIES PVT LTD (INDIA)
      • 22     ARRAYSTAR INC. (U.S)
      • 23     ASPIRA WOMEN HEALTH (U.S.)
      • 24     ATILA BIOSYSTEMS, INC (U.S.)
      • 25     AVANCE BIOSCIENCES,INC. (U.S.)
      • 26     BECTON, DICKINSON, AND COMPANY (U.S.)
      • 27     BERRY GENOMICS CO. LTD (CHINA)
      • 28     BGI GENOMICS (CHINA)
      • 29     BIO VIEW LTD. (ISRAEL)
      • 30     BIOCARTIS GROUP (BELGIUM)
      • 31     BIOCLAVIS LTD. (U.K.)
      • 32     BIOFLUIDICA (U.S.)
      • 33     BIOGAZELLE NV (BELGIUM)
      • 34     BIOMERIEUX, SA (FRANCE)
      • 35     BIONANO GENOMICS (U.S.)
      • 36     BIONEER, INC. (SOUTH KOREA)
      • 37     BIONIVID TECHNOLOGY PRIVATE LIMITED (INDIA)
      • 38     BIO-RAD LABORATORIES, INC. (U.S.)
      • 39     BIOSKRYB, INC. (U.S.)
      • 40     C2I GENOMICS, INC (U.S.)
      • 41     CANEXIA HEALTH (CONTEXTUAL GENOMICS) (CANADA)
      • 42     CAPITALBIO TECHNOLOGY INC. (CHINA)
      • 43     CAREDX (U.S.)
      • 44     CEGAT GMBH (GERMANY)
      • 45     CELEMICS, INC.(SOUTH KOREA)
      • 46     CELLMAX LIFE (U.S.)
      • 47     CHARLES RIVER LABORATORIES (U.S)
      • 48     CHIRAL TECHNOLOGIES, INC. (U.S.)
      • 49     CHUNLAB, INC. (SOUTH KOREA)
      • 50     CLEAVER SCIENTIFIC, LTD. (U.K.)
      • 51     COLOR GENOMICS (U.S)
      • 52     COMPLEMENT GENOMICS LTD (U.K.)
      • 53     CONGENICA (U.K.)
      • 54     COVARIS, INC.( U.S.)
      • 55     DANAHER CORPORATION (U.S.)
      • 56     DANTE LABS INC. (ITALY)
      • 57     DATAR GENETICS (INDIA)
      • 58     DESTINA GENOMICS LTD. (U.K.)
      • 59     DNA GENOTEK INC. (CANADA)
      • 60     DNA LINK, INC. (SOUTH KOREA)
      • 61     DNA WORLDWIDE GROUP LTD.(U.K.)
      • 62     DNAE GROUP HOLDINGS LTD. (U.K.)
      • 63     EIKEN CHEMICAL CO., LTD (JAPAN)
      • 64     ELLUME (AUSTRALIA)
      • 65     EMEDGENE TECHNOLOGIES LTD. (ISRAEL)
      • 66     EONE-DIAGNOMICS (SOUTH KOREA)
      • 67     EPIGENOMICS AG (GERMANY)
      • 68     EPPENDORF AG (GERMANY)
      • 69     EUROFINS SCIENTIFIC S.E(EUROFINS GENOMICS ) (LUXEMBOURG)
      • 70     EXACT SCIENCES CORPORATION (U.S.)
      • 71     FLORAGENEX, INC. (U.S.)
      • 72     FLUIDIGM CORPORATION (U.S.)
      • 73     FORMULATRIX, INC (U.S.)
      • 74     FREIBURG MEDICAL LABORATORY MIDDLE EAST LLC (UAE)
      • 75     FULGENT GENETICS (U.S.)
      • 76     FUSION GENOMICS CORP (CANADA).
      • 77     GEL COMPANY, INC. (U.S.)
      • 78     GENEDATA AG (SWITZERLAND)
      • 79     GENETIC TECHNOLOGIES GROUP (AUSTRALIA)
      • 80     GENEWIZ (U.S.)
      • 81     GENMARK DIAGNOSTICS (U.S.)
      • 82     GENOMATIX AG (GERMANY)
      • 83     GENOMEME (CANADA)
      • 84     GENOMIC DIAGNOSTICS (AUSTRALIA)
      • 85     GENOMIQA PTY LTD (AUSTRALIA)
      • 86     GENOMIX4LIFE SRL (ITALY)
      • 87     GENOSCREEN (FRANCE)
      • 88     GENOTYPIC TECHNOLOGY PVT. LTD.(INDIA)
      • 89     GENSCRIPT BIOTECH (U.S.)
      • 90     GENUITY SCIENCE (U.S.)
      • 91     GENXPRO, GMBH, (GERMANY)
      • 92     GNOME DIAGNOSTICS AND GNOME SCIENCES (U.S)
      • 93     GRACE BIO-LABS (U.S.)
      • 94     GRIFOLS, S.A. (SPAIN)
      • 95     GUARDANT HEALTH (U.S.)
      • 96     HALEENA BIOSCIENCES (U.K.)
      • 97     HELIX (U.S.)
      • 98     HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
      • 99     HOLOGIC, INC (U.S.)
      • 100     IGEN BIOTECH S.L.(SPAIN)
      • 101     IGENOMIX (SPAIN)
      • 102     ILLUMINA INC. (U.S.)
      • 103     IMGM LABORATORIES GMBH (GERMANY)
      • 104     IMMUCOR, INC. (U.S.)
      • 105     IMPACTLAB SRL (ITALY)
      • 106     IMPERIAL LIFE SCIENCES (ILS) (INDIA)
      • 107     INFANDX AG,(GERMANY)
      • 108     INFINITY BIOLOGIX LLC (U.S)
      • 109     INVITAE CORPORATION (U.S.)
      • 110     KOTAI BIOTECHNOLOGIES, INC.(JAPAN)
      • 111     LABGENOMICS (SOUTH KOREA)
      • 112     LABNET INTERNATIONAL (U.S.)
      • 113     LABORATORY CORPORATION OF AMERICA HOLDINGS (COVANCE) (U.S)
      • 114     LC SCIENCES LLC (U.S.)
      • 115     LCM GENECT SRL (ITALY)
      • 116     LGC LTD (LGC BIOSEARCH TECHNOLOGIES) (U.K)
      • 117     LIFEBIT (U.K.)
      • 118     LOOP GENOMICS (U.S.)
      • 119     LUCENCE DIAGNOSTICS PVT LTD (SINGAPORE)
      • 120     LUMINEX CORPORATION (U.S.)
      • 121     LXREPAIR (FRANCE)
      • 122     MACROGEN, INC. (SOUTH KOREA)
      • 123     MARIN BIOLOGIC LABORATORIES (U.S.)
      • 124     MDNA LIFESCIENCES (U.S.)
      • 125     MEDGENOME LABS LTD. (U.S.)
      • 126     MENARINI SILICON BIOSYSTEMS, INC. (ITALY)
      • 127     MERCK KGAA (GERMANY)
      • 128     MERIDIAN BIOSCIENCES (U.S.)
      • 129     MICROGENOMICS SRL (ITALY)
      • 130     MILTENYI BIOTEC (GERMANY)
      • 131     MIRXES PTE LTD (SINGAPORE)
      • 132     MYRAID GENETICS (U.S.)
      • 133     NANOCELLECT BIOMEDICAL, INC. (U.S.)
      • 134     NATERA, INC. (U.S.)
      • 135     NEBULA GENOMICS (U.S.)
      • 136     NEOGEN INFORMATICS (INDIA)
      • 137     NEOGENOMICS LABORATORIES, INC. (U.S)
      • 138     NOSCENDO GMBH, (GERMANY)
      • 139     NOVOGENE CO., LTD. (CHINA)
      • 140     NRGENE LTD.( ISRAEL)
      • 141     NUCLEIX LTD.( ISRAEL)
      • 142     OPKO HEALTH (U.S.)
      • 143     OPTIGENE LIMITED (U.K.)
      • 144     OXFORD NANOPORE TECHNOLOGIES LTD (U.K.)
      • 145     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (U.S.)
      • 146     PATHOQUEST (FRANCE)
      • 147     PENTABASE APS (DENMARK)
      • 148     PERKINELMER INC. (U.S.)
      • 149     PERSONAL GENOME DIAGNOSTICS INC. (U.S.)
      • 150     PETAGENE (U.K.)
      • 151     PHALANX BIOTECH GROUP (TAIWAN)
      • 152     PREDICTIVE TECHNOLOGY GROUP (U.S.)
      • 153     PROMEGA CORPORATION (U.S.)
      • 154     PRONTO DIAGNOSTICS LTD.(ISRAEL)
      • 155     PROXEOM (U.S.)
      • 156     PSOMAGEN, INC. (U.S.)
      • 157     PTC THERAPEUTICS VERIGENE (IRELAND)
      • 158     QIAGEN N.V.(NETHERLANDS)
      • 159     RANOMICS INC. (CANADA)
      • 160     REPROCELL INC (JAPAN)
      • 161     RPRD DIAGNOSTICS, LLC (U.S.)
      • 162     S2 GENOMICS (U.S.)
      • 163     SAPHETOR SA (SWITZERLAND)
      • 164     SCIGENOM LABS (INDIA)
      • 165     SEEGENE (SOUTH KOREA)
      • 166     SEQMATIC LLC (U.S.)
      • 167     SERVA ELECTROPHORESIS GMBH (GERMANY)
      • 168     SGS SA (TRAITGENETICS ) (U.S.)
      • 169     SHERLOCK BIOSCIENCES (U.S.)
      • 170     SHRADHA SAI LIFESCIENCE PVT LTD (INDIA)
      • 171     SINGLERA GENOMICS INC. (U.S.)
      • 172     SOPHIA GENETICS (U.S.)
      • 173     STAGEZERO LIFE SCIENCES (CANADA).
      • 174     STILLA TECHNOLOGIES INC. (FRANCE)
      • 175     STRAND LIFE SCIENCES (INDIA)
      • 176     SYD LABS (U.S.)
      • 177     SYSMEX CORPORATION(RIKEN GENESIS CO., LTD. (JAPAN)
      • 178     TAI DIAGNOSTICS (U.S.)
      • 179     TAKARA BIO INC. (JAPAN)
      • 180     TATAA BIOCENTER AB (SWEDEN)
      • 181     TBG DIAGNOSTICS LIMITED (AUSTRALIA)
      • 182     THERMO FISHER SCIENTIFIC, INC. (U.S.)
      • 183     TORAY INDUSTRIES, INC. (JAPAN)
      • 184     TWIST BIOSCIENCE (U.S.)
      • 185     VALIS GENOMICS (U.S.)
      • 186     VERITAS GENETICS (U.S.)
      • 187     VIROLOGY RESEARCH SERVICES LTD (U.K.)
      • 188     VOLITIONRX (U.S.)
      • 189     WELGENE BIOTECH CO.,LTD. (TAIWAN)
      • 190     YOURGENE HEALTH PLC ( EX5 GENOMICS) (U.K)